You are here
Health-Related Quality of Life in the Finnish Trial of Screening for Prostate Cancer
Neill Booth, Pekka Rissanen,Teuvo L.J. Tammela, Liisa Määttänen, Kimmo Taari,Anssi Auvinen
European Urology, Volume 65, Issue 1, January 2014, Pages 39–47
Editors' comments: Dr. Ricardo Caponero
Screening based on prostate-specific antigen levels is capable of reducing prostate cancer mortality but is hampered by the inability to identify selectively all men at risk of developing a potentially aggressive or deathly prostate cancer. Multivariate risk approaches including clinical data and comorbidity seem like the way forward.
Another problematic aspect is a potential damage in quality of life due to screening examinations and interpretation of results. We are used to be aware about quality of life related to treatments and disease, but not to secondary prevention.
In this trial, long-term follow-up of men in a population-based randomized trial suggests that, on average, a small advantage in health-related quality of life is likely for men with prostate cancer who were systematically invited for prostate cancer screening.